Table of Contents
✨ Onyx Summary
MassBio will host the 2025 Eisai R&D Day on October 20 at Eisai’s G2D2 Center in Cambridge, featuring panel discussions, poster sessions, and networking to showcase Eisai’s R&D priorities in neuroscience, oncology, and global health.
By fostering direct engagement between Eisai and U.S. biotech leaders, the event underscores the growing importance of cross-sector collaboration and strategic investment in driving the next wave of life-saving therapies.
MassBio is proud to present the 2025 Eisai R&D Day on October 20, 2025, at the Eisai Center for Genetics Guided Dementia Discovery (G2D2) in Cambridge, MA. Join Eisai and MassBio for an engaging afternoon of innovation and collaboration designed to deepen connections between Eisai and the U.S. biotech ecosystem.
What to expect
This exclusive gathering will spotlight Eisai’s commitment to human health care (hhc) through R&D and External Innovation in Neuroscience, Oncology, and Global Health, and offer a platform to explore shared scientific interests and partnership opportunities. The afternoon will feature a panel discussion led by R&D and Innovation leaders, and an interactive poster session and networking reception highlighting the science from Eisai and a select group of biotechs.
What you’ll hear
- Discover Eisai’s strategic R&D priorities and specific areas of interest across Neuroscience, Oncology, and Global Health
- Learn about Eisai’s External Innovation approach and how we work with biotech partners
- Meet Eisai’s corporate venture capital leadership and hear about investment priorities
- Gain clarity on collaboration models—from early-stage research to licensing and co-development
What they’re saying
“In response to the urgent need for new medicines, it is essential for scientists across life sciences, academia and start-ups, to collaborate by combining their specialized expertise, innovative ideas, and advanced technologies. This focus embodies the vision driving External Innovation at Eisai,” said Yoshiharu Mizui, Ph.D., President, Eisai Innovation, Inc. and Head of Collaboration and Incubation Department at Eisai. “Additionally, Eisai’s corporate venture capital organization, Eisai Innovation Inc., aspires to identify synergies between the scientific community and the Eisai network of companies through strategic investment in innovative assets and businesses, and embracing the latest research in cutting edge technologies, drug modalities and digital healthcare solutions to support Eisai’s near- and long-term strategy.”
Get closer
If you’re interested in a 1:1 conversation with Eisai’s External Innovation team, please contact Ben Boward, External Innovation Manager.